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http://www.biomedcentral.com/1471-2350/13/32RESEARCH ARTICLE Open AccessNo Association of nineteen COX-2 gene variants
to preclinical markers of atherosclerosis The
Cardiovascular Risk in Young Finns Study
Kati Lähteelä1, Tarja Kunnas1, Leo-Pekka Lyytikäinen2, Nina Mononen2, Leena Taittonen3, Tomi Laitinen4,
Johannes Kettunen5, Markus Juonala6, Nina Hutri-Kähönen7, Mika Kähönen8, Jorma S. Viikari6, Olli T. Raitakari9,
Terho Lehtimäki2 and Seppo T. Nikkari1*Abstract
Backgroud: The role of cyclooxygenase-2 (COX-2) single nucleotide polymorphisms has mostly been studied in
relation to advanced atherosclerosis, but little is known how they contribute to preclinical disease. In the present
study we analyzed whether COX-2 gene variants associate independently with the early subclinical markers of
atherosclerosis, carotid intima-media thickness and carotid artery distensibility in a population of young healthy
Caucasian adults.
Methods: SNPs for association analysis were collected from the COX-2 gene and 5 kb up- and downstream of it.
There were 19 SNPs available for analysis, four genotyped and fifteen imputed. Genotype data was available for
2442 individuals participating in the Cardiovascular Risk in Young Finns Study. Genotype imputation was performed
using MACH 1.0 and HapMap II CEU (release 22) samples as reference. Association analysis was performed using
linear regression with an additive model. PLINK was used for true genotyped SNPs and ProbABEL for imputed
genotype dosages. False discovery rate was used to take into account multiple testing bias.
Results: Two of the COX-2 variants (rs689470, rs689462) associated with distensibility (p = 0.005) under the linear
regression additive model. After adjustment with gender, age, body mass index and smoking status, association
between these SNPs and distensibility remained significant (p = 0.031). Subjects carrying the minor alleles had
higher value of carotid artery distensibility compared to the major allele homozygotes. However, after correcting
p-values for multiple testing bias using false discovery rate, association was lost. Another COX-2 variant rs4648261
associated with mean carotid intima-media thickness (p = 0.046) and maximal carotid intima-media thickness
(p = 0.048) in the linear regression model. Subjects carrying the minor allele of rs4648261 had lower values of mean
and maximal carotid intima-media thickness compared to subjects homozygote for major allele. After adjustments
the associations were lost with both mean and maximal carotid intima-media thickness. Thus, no statistically
significant associations of the studied COX-2 variants with carotid artery distensibility or carotid intima-media
thickness were found.
Conclusions: Our results suggest that in a Finnish population, there are no significant associations between COX-2
variants and early atherosclerotic changes in young adulthood.* Correspondence: seppo.nikkari@uta.fi
1Department of Medical Biochemistry, University of Tampere Medical School, Tampere, Finland
Full list of author information is available at the end of the article
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Atherosclerosis is the main pathologic process under-
lying cardiovascular disease. The chronic inflammatory
reaction in vessel wall has an important role in disease
initiation and progression [1].
Inflammation is partly regulated by prostaglandins
which are produced through the enzyme cyclooxygenase
(COX). Cyclooxygenase catalyzes the rate-limiting steps
in prostaglandin production from arachidonic acid.
COX-1 is constitutively expressed in most human tissues
under basal conditions. COX-2 expression is primarily
induced in response to inflammatory stimuli by growth
factors, mitogens, and cytokines [2].
The important role of COX-1 expression in platelets
leading to atherothrombosis has been clarified through
its inhibition with acetosalicylic acid. However, the role
of COX-2 activity in these events is still unclear [3].
COX-2 expression has been detected in endothelial cells,
smooth muscle cells, monocytes, and macrophages
within human atherosclerotic lesions [4,5]. Prostaglan-
dins produced by the COX-2 route may have impact on
the development of atherosclerosis by influencing inflam-
matory reaction, platelet function, leukocyte-endothelial
cell adhesion and smooth muscle cell proliferation and
migration [6].
The role of COX-2 has previously been studied in rela-
tion to advanced atherosclerosis with clinical complica-
tions, such as coronary artery disease [7,8] myocardial
infarction and ischemic stroke [9]. However, atheroscler-
osis begins in childhood and progresses for decades until
clinical complications such as myocardial infarction ap-
pear [10].
Contributions of genetic alterations would be expected
to manifest themselves in younger rather than in older
subjects. In fact, it has been suggested that low COX-2
level may enhance foam cell production and conse-
quently, increase the risk of atherosclerosis and cardio-
vascular disease [11]. Functional studies have been made
for only two of the tested SNPs (rs 20417, rs 5275), but
this does not necessarily mean that the others are not
functional [12-14]. There are 302 known SNPs in the
COX-2 gene available from the NCBI dbSNP human
database. In the present study we analyzed all the 19
COX-2 SNPs available from the HapMap II CEU (release
22) and their association with subclinical markers of ca-
rotid atherosclerosis, such as carotid intima-media thick-
ness (CIMT) and carotid artery distensibility (Cdist).
Methods
Subjects
The Cardiovascular Risk in Young Finns Study is a five-
center longitudinal cohort study of atherosclerosis risk
factors from childhood to adulthood [15], which has
been described in detail previously [16,17]. The firstcross-sectional survey involving 3596 subjects between
the ages of 3 and 18 years was conducted in 1980. The
latest follow-up was done in 2007. Genotype data for the
present analysis was available for 2442 individuals. All
subjects gave their written informed consents in 2001
and the local ethics committees in all five centers (Hel-
sinki, Kuopio, Oulu, Tampere and Turku) approved the
study.
Clinical characteristics and risk factors
Height and weight were measured, smoking habits and
history of diabetes were assessed with a questionnaire. A
random zero sphygmomanometer (Hawksley &Sons Ltd,
Lancing, UK) was used for blood pressure measure-
ments. The mean of three measurements was used in
the analysis. For the determination of serum lipids and
apolipoprotein B and A1 levels, venous blood samples
were drawn after an overnight fast. Lipid concentrations
and glucose were measured using standard methods
[18]. LDL cholesterol concentration was calculated
according to Friedewald formula. Fasting plasma highly
sensitive C-reactive protein (hs-CRP) concentrations
were analyzed by latex turbidometric immunoassay
(Wako Chemicals GmbH, Neuss, Germany).
Ultrasound measurements
Ultrasound examinations for baseline measure were per-
formed using Sequoia 512 ultrasound mainframes be-
tween September 2001 and January 2002 (Acuson,
Mountain View, CA) with a 13.0 MHz linear array trans-
ducer, as previously described [16]. The left carotid ar-
tery was scanned according to a standardized protocol.
The image in the carotid intima-media thickness mea-
surements was focused on the posterior wall of the left
carotid artery. A magnified image was recorded from the
angle showing the greatest distance between the lumen-
intima interface and the media-adventitia interface. A
minimum of four measurements of the common carotid
far wall were taken 10 mm proximal to the bifurcation in
order to derive mean CIMT. The between-visit (two vis-
its 3 months apart) coefficient of variation for CIMT
measurements was 6.4 %.
Several moving-image clips of the beginning of the ca-
rotid bifurcation and the common carotid artery with
duration of 5 seconds were acquired and stored in digital
format for subsequent offline analysis. To assess carotid
artery distensibility indices, the best-quality cardiac cycle
was selected from the 5-second image clips. The com-
mon carotid diameter 10 mm from carotid bifurcation
was measured from the B-mode images with ultrasonic
calipers at least twice in end diastole and end systole, re-
spectively. The means of the measurements were used
as the end-diastolic and end-systolic diameters. Ultra-
sound and concomitant brachial blood pressure
Table 1 Background characteristics of the study subjects
Mean SD N
Gender (male/female) 1123 (46.0 %)/1319 (54.0 %) 2442
Age (year) 31.4 5.0 2442
BMI (kg/m2) 25.1 4.4 2276
CIMT (mm) 0.58 0.09 2081
Cdist (%/10 mmHg) 2.17 0.75 2071
SBP (mmHg) 116.7 13.1 2084
DBP (mmHg) 70.8 10.8 2084
Total cholesterol (mmol/l) 5.1 1.0 2103
HDL cholesterol (mmol/l) 1.3 0.3 2101
LDL cholesterol (mmol/l) 3.3 0.8 2075
Triglycerides (mmol/l) 1.3 0.9 2103
Apolipoprotein B (g/l) 1.1 0.3 2103
Apolipoprotein A1 (g/l) 1.5 0.3 2103
hs-CRP (mg/l) 1.9 4.0 2103
Glucose (mmol/l) 5.1 0.9 2103
Smoking (yes/no) 511 (23.6 %)/1650 (76.4 %) 2161
SBP = systolic blood pressure, DBP= diastolic blood pressure.
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ity (Cdist = [(Ds - Dd)/Dd]/(Ps - Pd), where Ds is systolic
diameter, Dd is diastolic diameter, Ps is systolic blood
pressure, and Pd is diastolic blood pressure). Cdist mea-
sures the ability of arteries to expand as a response to
pulse pressure caused by cardiac contraction and relax-
ation. To assess reproducibility of ultrasound measure-
ments, 57 subjects were reexamined 3 months after the
initial visit (2.5 % random sample). The between-visit co-
efficient of variation was 2.7 % for carotid artery diastolic
diameter and 16.3 % for Cdist [19].
Genotyping and imputation
Genomic DNA was extracted from peripheral blood
leukocytes using a commercially available kit and Qia-
gen BioRobot M48 Workstation according to the man-
ufacturer’s instructions (Qiagen, Hilden, Germany).
Genotyping was done for 2556 samples using custom
build Illumina Human 670 k BeadChip atWelcome
Trust Sanger Institute. Genotypes were called using
Illuminus clustering algorithm. 56 samples failed San-
ger genotyping pipeline QC criteria (i.e., duplicated
samples, heterozygosity, low call rate, or Sequenom fin-
gerprint discrepancy). From the remaining 2500 sam-
ples one sample failed gender check, three were
removed due to low genotyping call rate (< 0.95) and
54 samples for possible relatedness (pi-hat> 0.2). 11766
SNPs were excluded based on Hardy-Weinberg equilib-
rium test (p ≤ 1e-06), 7746 SNPs failed missingness test
(call rate< 0.95) and 34596 SNPs failed frequency test
(minor allele frequency< 0.01). After quality control
there were 2442 samples and 546677 genotyped SNPs
available for further analysis [20].
Genotype imputation was performed using MACH 1.0
[21] and HapMap II CEU (release 22) samples as refer-
ence. After imputation there were 2543887 imputed
SNPs available. SNPs with squared correlation between
imputed and true genotypes ≥ 0.30 were considered well
imputed.
Statistical analysis
Phenotypes mean CIMT, maximal CIMT and Cdist were
transformed to normality using Box-Cox transformation.
Standard residuals were extracted from the model and
outliers ≥ 4 SD were removed. SNPs for association ana-
lysis were collected from the COX-2 gene and 5 kb up-
and downstream of it (chromosome 1, pos 186,635,945-
186,654,559). There were 19 SNPs available for analysis,
four genotyped and fifteen imputed. Association analysis
was performed using linear regression with additive and
recessive models. PLINK [22] was used for true geno-
typed SNPs and ProbABEL [23] for imputed genotype
dosages. To take into account multiple testing bias intro-
duced by testing 19 SNPs simultaneously, we used falsediscovery rate (FDR) [24] to correct the p-values. Q
values (= corrected p-values) less than 0.05 were consid-
ered significant. FDR calculations were done using R lan-
guage package ‘fdrtool’ [25].
Results
Background characteristics of the study population are
shown in Table 1. The participants´ mean age was
31.4 years at examination in 2001. Nineteen SNPs
included in the study are presented in Table 2. Data on
COX-2 variants associated with markers of early phase
atherosclerosis is presented in Table 3. Imputation qual-
ity was high. For rs689470, rs689462 and rs4648261 the
squared correlation between imputed and true genotypes
(Rsq) values were 0.999, 1 and 0.690 respectively.
Rs689470 and rs689462 were in 100 % linkage disequi-
librium. The minor T allele of rs689470 was in linkage
with the minor C allele of rs689462. These SNPs asso-
ciated with carotid artery distensibility (p = 0.005) under
the linear regression additive model (Table 3). After ad-
justment with gender, age, body mass index (BMI) and
smoking status, association between these SNPs and
Cdist remained significant (p = 0.031). Subjects with the
minor T allele of the rs689470 and the minor C allele of
the rs689462 had higher value of Cdist compared to the
major allele homozygotes. However, after correcting p-
values for multiple testing bias, association disappeared
(q = 0.137).
Another COX-2 variant rs4648261 associated with
mean CIMT (p= 0.046) and maximal CIMT (p = 0.048)
under the linear regression model. Subjects carrying the
Table 2 COX-2 variants included in the study
Variant Minor/major allele Minor allele frequency
Genotyped and imputed
rs2206593 T/C 0.074
rs5275 C/T 0.317
rs10911905 G/T 0.084
rs2143417 T/G 0.100
Imputed
rs4648304 T/C 0.009
rs689470 T/C 0.016
rs2066826 A/G 0.077
rs5277 C/G 0.174
rs4648262 T/G 0.0001
rs4648261 A/G 0.069
rs2745557 T/C 0.174
rs20417 C/G 0.100
rs689466 G/A 0.205
rs689462 C/A 0.016
rs12042763 A/C 0.287
rs2745559 T/G 0.174
rs11583191 T/C 0.081
rs2143416 G/T 0.111
rs2179555 G/A 0.088
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CIMT and maximal CIMT compared to subjects present-
ing major allele GG genotype. After adjustment with
gender, age, BMI and smoking status the associations
were lost with both mean CIMT (p = 0.116) and maximal
CIMT (p= 0.121). Also, after correcting for multipleTable 3 Association of the COX-2 variants with CIMT, Cdist an
Phenotype Variant Minor/major P P Q
allele unadjusted adjusted† adjuste
Mean carotid
intima-media
thickness (mm)
rs4648261 A/G 0.046 0.116 0.896
Max carotid
intima-media
thickness (mm)
rs4648261 A/G 0.048 0.121 0.477
Carotid
distensibility
(% /10 mmHg)
rs689470 T/C 0.005 0.031 0.137
rs689462 C/A 0.005 0.031 0.137
Total cholesterol
(mmol/l)
rs5275 C/T 0.014 0.007 0.017
LDL cholesterol
(mmol/l)
rs5275 C/T 0.009 0.006 0.022
† linear regression model, adjusted with gender, age, BMI and smoking status.
†† false discovery rate corrected p-values (= q-values) adjusted with gender, age, BM
hom major =major allele homozygote, het = heterozygote, hom minor =minor alleletesting bias, the associations were non-significant with
mean CIMT (q = 0.896) as well as with maximal CIMT
(q = 0.477).
One of the studied SNPs associated with serum choles-
terol values (Table 3). Subjects with the minor C allele of
the rs5275 had lower mean values of total cholesterol
(p = 0.014) and LDL cholesterol (p = 0.009) compared
with the major T allele. After adjustment with gender,
age, BMI and smoking status, associations remained sig-
nificant with total cholesterol (p = 0.007) and LDL chol-
esterol (p = 0.006). Moreover, associations remained
significant after multiple testing correction with total
cholesterol (q = 0.017) as well as with LDL cholesterol
(q = 0.022).
Finally, we also tested a recessive model in evaluating
the effect of SNPs on the markers of atherosclerosis. The
results were similar in both the additive and recessive
model. After adjustment with gender, age, BMI, smoking
status, and multiple testing correction in the recessive
model, the only associations that remained significant
were total cholesterol (q = 0.014) and LDL cholesterol
(q = 0.041) for rs 5275.
Discussion
We evaluated 19 single nucleotide polymorphisms in the
COX-2 gene for association with early structural and
functional changes of atherosclerosis. No significant
associations were found between SNPs under analysis
and early atherosclerotic changes in our study.
Decreased Cdist can be considered as an early sign of
functional atherosclerosis. It has been approved as an in-
dependent cardiovascular risk factor and predictor for
mortality in patients with advanced renal disease [26].
There are no previous studies of associations of COX-2d cholesterol values
Measured mean value Number of individuals
d †† hommajor het hom minor hom major het hom minor total
0.58 0.57 0.53 1583 99 4 1686
0.62 0.61 0.56 1583 99 4 1686
2.17 2.42 2000 71 2071
2.17 2.42 2000 71 2071
5.20 5.11 5.05 955 930 208 2093
3.31 3.24 3.16 940 921 204 2065
I and smoking status.
homozygote.
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with other markers of preclinical atherosclerosis in
young subjects.
The minor C allele of the rs20417 has been associated
with atherosclerotic plaques [7,27]. In contrast, Orbe et
al (2006) found that CIMT was reduced in the rs20417
minor C allele carriers. Moreover, Cipollone et al (2004)
reported that the minor C allele of the rs20417 was asso-
ciated with reduced risk of myocardial infarction (MI)
and stroke [9]. Other studies have not been able to repli-
cate the result for MI and stroke [28]. The rs20417 was
not associated with CIMT in our study population.
Concerning subclinical atherosclerosis in coronary, ca-
rotid and aortic arterial beds, Rudock et al (2009) investi-
gated eight COX-2 SNPs and their relationship to
calcified plaques in subjects with type 2 diabetes mellitus
[27]. They found that three SNPs (rs689466, rs2066826
and rs20417) were associated with coronary or carotid
calcified plaques. These three variants were included in
our study but they did not associate with CIMT para-
meters or Cdist. Moreover, we could not do a subgroup
analysis, since our study included only 24 subjects who
had type 1 diabetes. Since CIMT and Cdist are signifi-
cantly associated with high LDL-cholesterol, elevated
blood pressure, obesity and smoking [16,19], it is obvious
that genetics, e.g. the variation in COX-2 genotype, may
be of only minimal importance and difficult to reveal.
Studies showing association with cardiovascular dis-
ease for several other SNPs included in this study have
already been published. For the minor C allele of rs5275
a beneficial role has been proposed [8,29]. For rs689466
minor G allele, there is a report of no effect [8] and a
beneficial effect [27]. Rs2066826 minor A allele has also
had an beneficial effect [27]. None of these SNPs were
associated with CIMT or Cdist in our study.
Subjects with the minor C allele of rs5275 had lower
mean values of total cholesterol and LDL cholesterol
compared with the major T allele. The difference was
small and not clinically relevant. However, in line with
our results, there is a previously reported interaction of
rs5275 and alcohol in relation to plasma cholesterol
levels, where the minor allele carriers with low alcohol
intake had the lowest lipid levels [8].
A major limitation of the present study is that the
minor allele frequency of many COX-2 variants was very
low. For rs689470 and rs689462 it was 0.016. Therefore,
there were no rare allele homozygotes present in our
data and the frequencies of the wild type and heterozy-
gote genotypes were 0.97 (n = 2000) and 0.03 (n = 71) re-
spectively. Minor allele frequency of rs4648261 was
slightly better, 0.069. Still, there were only four homozy-
gotes for the minor allele and the frequencies of the wild
type and heterozygote genotypes were 0.94 (n = 1583)
and 0.06 (n = 99) respectively. The number of subjectsfor minor allele homozygotes and heterozygotes is too
small to obtain valid results in association study con-
cerning such a complex disease as atherosclerosis.
Conclusions
In conclusion, our results suggest that in a Finnish popu-
lation, there are no significant associations between
COX-2 variants and early atherosclerotic changes in
young adulthood.
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